Background: The development of effective adjuvant therapies for the treatment of high-risk melanoma patients is critical for the prevention of metastatic disease and im-
Introduction
Cutaneous malignant melanoma is responsible for approximately three-fourths of all skin cancer-associated deaths (1) . The incidence of melanoma in the Caucasian population has continued to increase at an alarming annual rate of 6% (2) . Whereas the estimated lifetime risk for malignant melanoma in the U.S. was 1 in 1500 in 1935, it is expected to be 1 in 75 by the year 2000 (2) . In addition, malignant melanoma rates are increasing faster than any other cancer among men and are second only to lung cancer among women (3) . Thin primary melanomas (thickness <0.75 mm) are successfully treated with surgical excision with a 5-year survival rate of >98% (4) . However, the 5-year survival rate of patients with thick primary cutaneous melanomas (>4.0 mm) is <50% (4) . Patients with nodal metastatic disease have a 36% survival rate at 5 years, which decreases to only 5% if distant metastases are present (5) .
Treatment options beyond surgery that may prevent recurrent disease are limited for patients with thick primary melanomas or those with melanoma present in regional lymph nodes, although the search for effective adjuvant therapies for the treatment of these high-risk melanoma patients is actively pursued. These attempts have included trials with interferons, specific and nonspecific immunotherapy, adjuvant chemotherapy and chemoimmunotherapy, isolated limb perfusion, adjuvant radiation therapy, adjuvant hormonal therapy, and adjuvant retinoid therapy (6) (7) (8) (9) (10) (11) (12) (13) . The development of approaches employing active specific immunotherapy with therapeutic melanoma vaccines was prompted by clinical observations, suggesting an important role of the immune system in melanoma (7) . Therapeutic vaccines employing purified gangliosides, shed antigens, specific isolated peptides, mechanical or viral melanoma cell lysates, and allogeneic or autologous whole cell preparations have been used as postoperative treatments for prevention and regression of tumor metastases because of the potential ability of the immune system to distinguish tumor cells from normal cells and selectively destroy the tumor (8) (9) (10) (11) (12) (13) .
Most of these approaches have shown little survival advantage over surgical therapy only and the interpretation of results is complicated by problems with experimental design that are often inherent in small clinical studies (1 3).
Additionally, little information about the host immunologic response to these therapeutic agents has been obtained. However, several of these approaches have suggested promising results and several randomized phase III trials are in progress (14) (15) (16) . Recently, high-dose interferon a-2b (Intron-A; Schering Plough) has been shown in a randomized, controlled trial to have a positive effect on disease-free and overall survival in the postsurgical adjuvant setting for high-risk melanoma, making this agent the current standard of care for these patients (17) . These (24) (25) (26) and the 33% survival rate at 10 years observed in historical studies in which patients with occult lymph node disease were included (27, 28 The methods used for the preparation and administration of the NDV oncolysate have been previously described (23, 29) . Briefly, the lysed products from NDV-infected monolayers of 10 lines of human melanoma cell lines established from melanoma patients were infected with NDV strain 73T. Cell lines were successfully established from only four of the patients in group I who were enrolled to receive NDV oncolysate therapy. The lysed cellular products and live NDV were concentrated 10-fold and stored at -70°C prior to use (23) . Patients received allogeneic oncolysates in rotating combinations (23 (30) was used to assess length variation of the CDR3 loop in the TCR 1B chain. In brief, total RNA was used for first-strand cDNA synthesis using a TCR /3-chain C-region primer (Cf3-14:5' CTC AGC TCC ACG TC 3'). An aliquot of cDNA was then used for subsequent TCR 3-specific PCR amplification using a radiolabeled C,B reverse primer, and upstream VP3-specific forward primers in multiplex combinations as described previously (31) (35) .
Monoclonal antibodies to other TCR VP3 segments used for this study were obtained from the TCR monoclonal antibody workshop (36) .
Immunofluorescent Staining and FACS Analysis
We were able to triple stain simultaneously for CD57, CD8, and various Va and V,B segments of the TCR by using an isotype-specific matched protocol of first and second stage reagents that we have previously described (37) . Briefly, 50 (38) . Figure 2 shows an example of such an analysis in one individual. Note that there are numerous dominant bands in the CD8 subset (lanes A-L, Fig. 2A ), in contrast to the apparent gaussian distribution of TCR VP3 length seen in the CD4 subset ( lanes A-L, Fig. 2B ). Figure 3 summarizes the results of oligoclonal expansions detected in 27 melanoma patients treated with NDV oncolysate and 23 agematched normal individuals. The mean number Figure 2A and clonality in the CD8+ T cell population (as determined by the CDR3 length assay) with cellular expansions within the CD28-CD57+ subset (as assessed by FACS analysis with VP3-specific antibodies) (39) . In order to demonstrate this correlation in melanoma patients treated chronically with NDV oncolysate, we performed three color flow cytometric studies on these patients. Figure 5 . The mean percent of the CD8 T cell compartment that was occupied by expansions was 4.09 in the control group and 8.85 for the melanoma patients (p < 0.003). These frequencies of expansions are likely to be underestimates of the actual frequencies due to the limited range of TCR V segments for which specific antibodies are available.
Functional Potential of the Clonally Expanded CD8+CD57+ T Cells Whole blood was stimulated with phorbol myristate acetate (PMA) and ionomycin to determine the functional capacity of these cells to express cytokines. upon stimulation, and 83% make TNF-a; however, they make very little IL-2 either in the resting or activated state. In results not shown, these VP3 11 expanded cells also express TIA-1, an antigen that is expressed by cells that have cytotoxic potential, and cell lines generated from these expanded clones can kill in redirected cytotoxicity assays.
Discussion
The use of Newcastle disease virus and other virus therapies in the treatment of advanced neoplastic disease dates back several decades (40, 41) . NDV is a paramyxovirus also known as avian pneumoencephalitis virus. While it is a serious viral disease of birds marked by involvement of the respiratory and nervous systems, humans usually develop only a temporary conjunctivitis if they become infected by direct handling of sick birds. NDV has been evaluated as an anticancer agent because this virus has been shown to have direct toxic effects on tumor cells as well as indirect effects that appear to be mediated through stimulation of the host immune system (40) (41) (42) (43) . NDV has been utilized alone and in combination with autologous and allogeneic tumor cells to generate viral oncolysates that can be delivered as a vaccine to patients with advanced metastatic disease (18, (44) (45) (46) (47) . Two main strains of NDV have been the focus of most clinically related studies. These are the nonlytic Ulster strain and the lytic NDV 73T strain. The latter was developed in 1965 by Cassel and Garrett by passaging NDV 379-SI through Ehrlich ascites tumor cells in vitro 73 times and in vivo 13 times to eliminate the neurotrophic properties of this strain (44) . NDV 73T was found to exhibit limited affinity for nervous tissue when tested in mice, rabbit, guinea pig, Syrian hamster, and Wistar albino rat. The NDV 73T strain was used to prepare viral oncolysates in the phase II clinical trial of adjuvant immunotherapy for malignant melanoma described in this study (29) .
We have reviewed the clinical outcome and immunologic effects of long-term NDV oncolysate vaccination in the treatment of high-risk AJCC stage III malignant melanoma patients following therapeutic lymph node dissection. The 15-year survival for two groups of patients accrued independently and treated with NDV oncolysate is 59% for group I and 53 % for group II with an overall survival of 55%. The survival of patients in groups I and II does not differ significantly from each other, indicating the reproducibility of the results obtained with this adjuvant therapy in patients accrued over an 8-year period. Additionally, similar survival rates were observed regardless of the number of lymph nodes found to be positive for metastatic melanoma at the time of therapeutic lymph node dissection prior to initiation of adjuvant NDV oncolysate treatment. No survival advantage was observed in the small number of patients receiving NDV oncolysate made from both autologous and allogeneic melanoma cells; 50% of these four patients survived.
The current analysis of 15-year survival indicates that the protective effect on survival from this therapy that was observed at 10 years is continued in these patients (23) . Because this phase II study was conducted with a small number of patients and did not include a control untreated patient group, caution must be exercised in drawing conclusions regarding the efficacy of this therapeutic approach (13) . However, there appears to be substantial improvement in the survival of these NDV oncolysate-treated patients compared with the survival of patients with either therapeutic dissection of palpable nodes or elective lymph node dissection as reported in the literature. Patients with melanoma metastatic to regional lymph nodes (AJCC stage III) requiring therapeutic dissection of palpable lymph nodes have a historical 10-year survival rate of 6-15% (24) (25) (26) . More recent studies of AJCC stage III patients have shown 10-year survival rates ranging from 33% to 41% (27, 28, 48) and a 15-year survival rate of 38% (48) . The improved survival in the latter studies appears to relate to the use of elective lymph node dissection, which provides for removal of early, nonpalpable lymph node disease, compared with the older studies in which therapeutic lymph node dissection was performed only for palpable lymph nodes. Overall, our current survival results and those obtained in the earlier phases of this study with NDV oncolysate have consistently shown a more favorable outcome than historical controls (18) (19) (20) (21) (22) (23) (52) . In another study of 33 patients, a decrease in CD57+ cells was observed in patients with advanced or disseminated malignant melanoma (53) . These observations point to a role for CD8+CD57+ cells in an effective immune defense against these tumors.
Our findings clearly demonstrate an increased clonality within the CD8 T cell subset of NDV oncolysate-treated patients (see Fig. 3 T cell population in treated melanoma patients, compared with normal controls (see Fig. 5 ). This subset of T cells can be expanded in the setting of autoimmune diseases, bone marrow transplantation, and chronic viral infections and is also seen in some normal individuals, usually in an older age-groups (39) . The control group in these studies was taken from the same age range as that of the melanoma subjects. These CD8 clonal expansions most likely represent terminally differentiated effector cells; this hypothesis is supported by our findings that these clonally expanded cells produce large amounts of TNF-a and IFN-y (Fig. 6 ) and function in cytotoxicity assays. We have observed in several individuals that these clonal expansions are present for years, a finding that suggests a response to a chronic and/or recurrent immune stimulus (37) .
In tabulating these data we detected expan- Two of these VP3 segments that were clonal in both sites were also expanded in the CD8+CD57+ subset of PBL. These observations suggest that the clonal expansions detected in peripheral blood are reflective of the ongoing immune response at the tumor site in at least some instances.
Viral oncolysates have been shown to induce remission, prolong life with reduced tumor burden, or decrease relapse rates for human cancers, although no significant effect on survival has yet been reported in large, randomized clinical trials using adjuvant viral oncolysates (13, 18, 40, 41) . NDV has been used to induce tumor regression and its mode of action is postulated to occur, at least in part, through the cytolytic activity of T cells through their production of TNF-a. Lorence et al. have reported that T73 and the wild-type isolate of NDV are potent inducers of TNF-a pro-duction by human PBMCs (43) . In the current study it is unclear whether the presence of live NDV or the chronicity of the treatment is primarily responsible for the improved outcome in the patient population. To address this issue, studies are in progress in which chronic immunization of mice with the T73 oncolytic strain of NDV will be compared with the nonlytic Ulster strain in a melanoma model system. The overall sustained clinical benefit of NDV oncolysate as an adjuvant immunotherapeutic agent and the demonstrated involvement of CD8 T cells in the ensuing immune response suggest that further investigation of the potential anti-tumor activity of CD8 T cells in these patients is warranted.
